No link between COVID-19 vaccines & sudden deaths: ICMR-AIIMS Study

​Union Minister of Health and Family Welfare said that extensive studies by the Indian Council of Medical Research (ICMR) and All India Institute of Medical Sciences have conclusively established no linkage between COVID-19 vaccines and sudden deaths among adults post-COVID-19.

The Ministry noted that studies conducted by ICMR and the National Centre for Disease Control (NCDC) affirm that COVID-19 vaccines in India are safe and effective, with extremely rare instances of serious side effects. The incidence of sudden cardiac deaths can result from a wide range of factors, including genetics, lifestyle, pre-existing conditions, and post-COVID complications. The ICMR and NCDC have been working together to understand the causes behind sudden, unexplained deaths, especially in young adults between the ages of 18 and 45 years.

Akashvani correspondent reports that to explore this, two complementary studies were undertaken using different research approaches-one based on past data and another involving real-time investigation. The findings of the first study have conclusively shown that COVID-19 vaccination does not increase the risk of unexplained sudden death in young adults. The second study is currently being conducted by AIIMS, New Delhi.

Early analysis indicates that heart attacks, or myocardial infarction, continue to be the leading cause of sudden death in this age group. The studies offer a more comprehensive understanding of sudden unexplained deaths in young adults in India. They also reveal that COVID-19 vaccination does not appear to increase the risk, whereas the role of underlying health issues, genetic predisposition and risky lifestyle choices does play a role in unexplained sudden deaths. Scientific experts have reiterated that statements linking COVID vaccination to sudden deaths are false and misleading, not supported by scientific consensus.

Related Posts

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

Mumbai: Cancer patients and their caretakers in India often spend long, arduous hours in hospitals for conventional treatment. But now with the launch of the world’s first subcutaneous or under-the-skin…

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

New Delhi:  The Central Drugs Standard Control Organization (CDSCO) and state drug regulatory authorities have intensified drug safety crackdown as substandard and spurious medicine cases have risen during the last…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

Piramal Pharma Gets 3 USFDA Observations at US Facility

Piramal Pharma Gets 3 USFDA Observations at US Facility

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

Kota: Uproar After 4 Women Die in Government Hospital; Relatives Refuse to Take Bodies

Kota: Uproar After 4 Women Die in Government Hospital; Relatives Refuse to Take Bodies

ICMR transfers three Indigenous Medical Technologies to Industry at National Technology Day 2026

ICMR transfers three Indigenous Medical Technologies to Industry at National Technology Day 2026